CG
BEAM icon

Cutler Group’s Beam Therapeutics BEAM Stock Holding History

Cutler Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$1K – 3572
2023
Q1 		$1K Buy
+100
New +$3.95K ﹤0.01% 3335
2021
Q2 		– Sell
-500
Closed -$2K – 5680
2021
Q1 		$2K Buy
+500
New +$47.6K ﹤0.01% 4859

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Cutler Group's BEAM Position: Q1 2024 in Review

Cutler Group sold out of Beam Therapeutics (BEAM) in Q1 2024, closing a stake of 50 shares — an estimated $1K sold.

Cutler Group first reported a position in BEAM in Q4 2020 and held it in 7 quarters. The position peaked at $204K in Q4 2020. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

  • Cutler Group reported no remaining Beam Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 50 Beam Therapeutics shares in Q1 2024, an estimated $1K.
  • Cutler Group first reported a position in Beam Therapeutics in Q4 2020 and held it in 7 quarters.
  • Cutler Group's Beam Therapeutics position peaked at $204K in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.